NEIGHBOURS CALLING:      Dubai      Malaysia     Nepal     Bhutan
  HOME       Contact Us      Hire Us       Domestic Airlines        Railway Enquiry     Railway Booking     Hotels Abroad
CORONAVIRUS CASUALTIES (July 3):- GLOBAL:- Total Cases: 1,10,53,545; Total Deaths: 5,25,410 Recovered: 61,91,434 BELGIUM:- Total Cases: 61,727; Total Deaths: 9,765 BRAZIL:- Total Cases: 15,02,424; Total deaths: 62,045 CANADA:- Total Cases: 104,936; Total Deaths: 8,644 CHINA:- Total Cases: 83,542 ; Total Deaths: 4,635 FRANCE:- Total Cases: 1,66,378; Total Deaths: 29,875 GERMANY:- Total Cases: 196,738; Total Deaths: 9,064 INDIA:- Total Cases: 6,33,381; Total Deaths: 18,320 INDONESIA:- Total Cases: 60,695; Total Deaths: 3,036 IRAN:- Total Cases: 2,35,429; Total Deaths: 11,260 ITALY:- Total Cases: 2,40,961; Total Deaths: 34,818 JAPAN:- Total Cases: 18,874 ; Total Deaths: 975 MEXICO:- Total Cases: 2,38,511; Total Deaths: 29,189 NETHERLANDS:- Total Cases: 50,335; Total Deaths: 6,113 PHILIPPINES:- Total Cases: 40,336; Total Deaths: 1,280 RUSSIA:- Total Cases: 6,67,883; Total Deaths: 9,859 S KOREA:- Total Cases: 12,967; Total Deaths: 282 SPAIN:-Total Cases: 2,97,183; Total Deaths: 28,368 SWEDEN:- Total Cases: 70,639; Total Deaths: 5,411 SWITZERLAND:-Total Cases: 32,101; Total Deaths: 1,965 UAE:- Total Cases: 49,469; Total Deaths:317 UK:- Total Cases: 2,83,757; Total Deaths: 43,995 US:- Total Cases: 28,54,976; Total Deaths: 1,31,663 - India Travel Times.Com   [Estd: 1998]       * * *    Travel, More Travel, Travel Means A Million Things     * * *    

Branded corona drugs FabiFlu, Cipremi ready for supplies

The two experimental medicines for coronavirus have been given the green signal by the DCGI to manufacture and market in India. Glenmark is making FabiFlu (Favipiravir) and Cipla is making Cipremi (Remdesivir). Hetero Drugs is also making its generic version of Remdesivir. Called Covifor, this one costs Rs 30,000 per patient for 6 vials for a course of five days, according to reports. Cipla has not determined its price.

NEW DELHI, June 22: Two more experimental medicines for coronavirus are set to hit the markets in India in the coming few days. These are FabiFlu and Cipremi. Both have been given the goahead for manufacture and supply by the DCGI (Drug Controller-General of India) under an accelerated process.

They have been approved for restricted emergency use in mild to moderate cases of coronavirus infection. Being termed as responsible medication, patients' written consent has to be obtained before the administration of the drug.

FabiFlu, an oral medicine, is the brand name of the Indian make of Favipiravir of Japan, where it is in use as a drug for flu, and in India it is the first authorisation. Mumbai-based Glenmark Pharmaceuticals is the manufacturer of FabiFlu. Glenmark said it has completed Phase III clinical trials, which also involved Umifenovir in combination.

The company claims 88% improvement in the condition of the patients in four days, a rapid decrease in the viral load. Russia, China and Japan have successfully tried the medicine on covid patients with remarkable results, it is said.

It will be a prescription drug costing Rs 103 per tablet. According to the prescribed course, the dose is 1,800 mg twice on first day followed by 800 mg twice a day up to day 14. Glenmark claims it can be administered in comorbid conditions also.

Cipremi is the name Cipla has given to Remdesivir, which is originally Gilead Sciences' doubtful panacea first developed for treating Ebola in 2014. Imported Remdesivir is already on the Indian Government's approved list and is currently administered across the country. Gilead has given the licence to Cipla to manufacture and market the medicine in India.

Cipla's shares have moved north. Gilead has signed non-exclusive licensing pacts with 4 other pharmaceiticals also in the region. This is said to be the only medicine that carries the Emergency Use Authorisation (EUA) from the US FDA for the treatment of coronavirus. Remdesivir is administered intravenously in advanced cases. Cipremi is said to produce better results than Lopinavir and Ritonavir.

Like Cipla, Hyderabad-based Hetero Drugs is also making its generic version of Remdesivir called Covifor. According to a report, it will cost Rs 30,000 per patient for 6 vials for a course of 5 days. Cipla has not yet priced its version.

Previous Files

Custom Search